Drug repositioning (DR) is a strategy to discover the new pharmacological effects of drugs sufficiently approved in terms of safety and pharmacokinetics in humans and to develop therapeutic agents for other diseases.
The following are major advantages of DR in pharmaceutical development:
Using our own library targeted for compounds from drugs approved in Japan, we have performed various screenings to advance DR (including drugs for COPD or dry eye).We also offer our library to partners for free and work together for DR promotion. Since 2018, we have provided not only the libraries but also research grants for the expansion of collaborative research with academic organizations.
To enhance the pharmacological effect of an approved drug from screening or obtain a substance patent, we have created a new substance by synthesizing derivatives with the approved drug as a lead compound (for example, LT-3001, LT-3002).
Many pharmaceutical companies have compounds discontinued from clinical development (shelved drugs) because of the lack of a pharmacological effect in spite of confirmation of clinical safety. Successful discovery of a pharmacological effect with DR development of a therapeutic agent for other diseases will bring great advantages to these companies. Our business includes DR of these compounds commissioned by major companies.
※The drugs to be developed in both processes are administered through the same route
The DR strategy enables rapid, cost-effective, certain development of safe pharmaceutical products.